#iipr

Innovative Industrial Properties, Inc. (NYSE:IIPR) is carving a niche in the cannabis sector by providing vital real estate solutions for the rapidly growing medical cannabis industry. With its strategic property acquisitions, solid financial growth, and diversified portfolio, IIPR is well-positioned to continue its upward trajectory in the evolving market.

Innovative Industrial Properties Inc. Sees 6.07% Increase in Bottom-line for Q4 2023, Showcasing Strong Financial Performance https://csimarket.com/stocks/news.php?code=IIPR&date=2024-02-28150640&utm_source=dlvr.it&utm_medium=tumblr

What a great event Fantasia 2022 was to welcome freshers to the campus of IIPR which they will call home for coming years. The Chief Guest was Ms. Swarnalata Iyer, Adjunct Professor Christ University, Fr. Praveen and Fr. Alex were also in their August attendance. The event's most memorable acts being Chammak Chalo dance from Group 3,  'Don't You Wanna Be Evil' duet from Group 1 the Poetry Drama and Comedy Set from Group 2. Group 3 stood as the winner for ' 15 mins of Fame' The Mr and Ms. Fresher's had many performances and interview questions yielding Chris Gloryson as Mr Fresher and Ojasvi Mishra as Ms Fresher 2022 The night ended with a brief dance party. Another important part of the event was Chris's story of how he wanted to have a music career but his parents forced psychology on him which is the truth of many in our youth.

#IIPR #wallstreet #newyork #stock #money #钱 #돈 #כסף #お金 #पैसे #soldi #penger #Деньги #Geld #imali #pénz #para #เงิน #dinero #peniaze #dinheiro #argent #پول #raha #Travel #viaggio #viaje #السفر #旅行 #旅行 #Voyage https://www.instagram.com/p/CCqAihVHCeU/?igshid=1ekszgt9n7qv8

With U.S. federal legalization gaining momentum, we looked at three lower-risk stocks that will still see substantial benefits from legalization. #marijuanastocks #potstocks Read the full article

Innovative Industrial Properties (IIPR) Innovative Industrial Properties (NYSE: IIPR) is technically not a marijuana company, but a real estate investment trust (REIT). It is the only REIT of its kind that provides real estate and facilities designed for the growing of cannabis. The fact that it does not process or sell weed insulates them from Schedule I. Moreover, since they can also serve both hemp and medical marijuana growers, they could theoretically operate in all 50 states. IIPR stock differs from most other marijuana stocks in another way—it earns a profit and pays dividends. In fact, it has also expanded by buying properties from struggling marijuana companies, which it then leases back. IIPR also will benefit from the industry’s massive growth. Analysts forecast earnings growth of 140.0% this year. They also expect triple-digit profit increases in fiscal 2020 when they predict a 106.7% increase. Since REITs have to pay out at least 90% of their net income in dividends, that cash will come right back to investors. Currently, the company pays $3.12 per share in annual payouts, a yield of about 3.8%. At a forward P/E ratio of just over 22, IIPR stock is an intriguing way to not only play marijuana growth but also to earn cash flow as well. The Scotts Miracle-Gro Company (SMG) Most consumers know Scotts Miracle-Gro (NYSE:SMG) best for their lawn fertilizer. However, the Marysville, Ohio-based lawn chemical company has become an emerging player in the marijuana industry. Through a division called Hawthorne Gardening Co., Scotts provides lighting, nutrients, hardware, and other products designed for growing cannabis. Hawthorne works with both hobbyists and commercial growers. In the fourth-quarter, Hawthorne increased its sales by 38%, driven mostly by growth in the U.S. Hawthorne also accounted for $210 million of the Scotts Miracle-Gro’s $497.7 million in sales. With that kind of growth, Scotts may soon become a cannabis rather than a fertilizer company in the minds of consumers. SMG stock also offers a safer, lower-cost segue into the cannabis industry. Thanks to marijuana, the company registers double-digit profit growth, with a 12.8% earnings increase predicted for the year. Moreover, it trades at less than 1.9 times sales. Hence, the massive drop that hit other weed stocks left SMG mostly unscathed. At about $107 per share as of the time of this writing, it trades about 7% below the 52-week high of $114.63 per share. For investors wanting marijuana-driven growth without exposure to either wild stock price swings or Schedule I, SMG stock should serve them well. GW Pharmaceuticals (GWPH) While GW Pharmaceuticals (NASDAQ: GWPH) is based in the U.K., they currently sell the only FDA-approved product based on cannabis and derive the majority of their revenue in the U.S. GW Pharma has made a name for itself selling Epidyolex, a marijuana-based treatment for epilepsy that received FDA approval in 2018. Since approval, more than 15,000 patients have tried the cannabis-based therapy. In the third quarter, Epidyolex brought in $86.1 million in revenue, with about 3,000 additional patients beginning treatment during the third quarter alone. Thanks to the approval of this drug, analysts expect revenue to rise from just $15.88 million last year to $302.09 million in 2019. They forecast a further increase in revenue to $559.04 million in 2020. Moreover, profitability could come as early as next year. Like many marijuana stocks, GWPH stock has fallen into a bear market in the spring and summer. As a result, it has fallen about 45% from its 52-week high. However, this has taken the price-to-sales ratio to about 15, well below the near-100 levels it had reached in the spring. With massive revenue growth driven by an FDA-approved product, GWPH should emerge as a long-term winner in the medical marijuana space. Read the full article